An unusual complication of bortezomib therapy: Acute pancreatitis

Gupta, Harish; Bansal, Raghav; Khanna, S. K.; Saxena, Sangeeta

doi:10.4103/0971-4065.127928

Cited by 9 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No details of any potential relationship between ixazomib and acute pancreatitis in this patient were given. There have, however, been several case reports on bortezomib-induced acute pancreatitis [6,7,8], and the lack of reported cases of ixazomib- and carfilzomib-associated acute pancreatitis may be in part due to their relatively recent regulatory approval in 2015 [9] and 2012 [10], respectively, compared to that of bortezomib in 2003 [11]. Alternatively, the relative risk for acute pancreatitis could also be influenced by the difference in the boronic-acid active moiety of bortezomib and ixazomib versus the epoxyketone active moiety of carfilzomib as well as differences in proteasome inhibitor specificity, as bortezomib also has activity against nonproteasomal serine and cysteine proteases [12].…”

Section: Discussionmentioning

confidence: 99%

Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient

2018

View full text Add to dashboard Cite

Background: Acute pancreatitis is an uncommon complication of anti-myeloma agents. Ixazomib is a first-in-class oral proteasome inhibitor to receive regulatory approval for the treatment of multiple myeloma. This case report describes the first case of ixazomib-associated pancreatitis. Case Presentation: An 80-year-old female with relapsed multiple myeloma presented with severe diarrhea, nausea, vomiting, abdominal pain, and acute renal failure 3 weeks after starting ixazomib and dexamethasone for disease progression. An extensive workup revealed acute pancreatitis without a definitive cause. Her condition improved with supportive measures and the discontinutation of ixazomib. The latter was suspected as the probable etiology of the patient's acute pancreatitis, given no clear alternative causes and the temporal relationship between initiating ixazomib and the development of her symptoms. Conclusions: Practitioners should include acute pancreatitis as part of their differential diagnosis in patients on ixazomib treatment who present with gastrointestinal symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient

2018

View full text Add to dashboard Cite

show abstract

“…G. Talamo et al [37] представили серию из 8 случаев бортезомибиндуцированного ОП. В настоящее время патофизиологический механизм развития ЛИП, ассоциированного с приемом бортезомиба, остается неясным [34,38,39]. М. Gotoh et al [40] опубликовали клинический случай пациента с меланомой, у которого после терапии бортезомибом повысился уровень триглицеридов; подобные данные были представлены и в других литературных источниках [33,41], при этом уровни триглицеридов были повышены не экстремально.…”

Section: ингибиторы протеасомunclassified

Antineoplastic agents associated with the development of drug-induced pancreatitis

2021

View full text Add to dashboard Cite

The frequency of drug-induced pancreatitis (LIP) is from 2 to 5% of all cases of acute pancreatitis (OP), but it is much more common in risk groups – among children and HIV-infected patients. The use of a number of drugs (drugs) is associated with the development of lipids, among them a special place is occupied by antitumor drugs due to the great medical and social significance of oncological diseases and the appearance in recent years of a large number of new antitumor drugs. The purpose of this review was to review the literature data on antitumor drugs, the use of which is associated with the development of lipids. LI OP developed in 1.8% of patients treated with nivolumab or pembroluzumab. In total, in 14 phase 1-3 studies on the efficacy and safety of ipilimumab, the development of OP was reported in less than 1% of the subjects. Therapy with molecular-targeted targeted drugs, such as tyrosine kinase inhibitors (TKI) or other representatives of the kinase inhibitor class, is also associated with the development of OP. The HP database of the World Health Organization (WHO, World Health Organization Adverse Drug Reaction database) contains reports of individual clinical cases of OP development during treatment with proteosome inhibitors and antibody-drug conjugates. It is known that the following antitumor drugs are also associated with the development of pancreatitis: 6-mercaptopurine, L-asparaginase, tamoxifen, cisplatin, cytarabine, ifosfamide, paclitaxel, docetaxel, oxaliplatin, capecitabine, periwinkle alkaloids, cytosine, cisplatin, interferon alpha-2b, doxorubicin, tamoxifen, gefitinib, vinorelbine, levamizole, methotrexate, 5-fluorouracil, capecitabine, trans-retinoic acid.

show abstract

“…The mechanism of bortezomib-induced pancreatitis is not known. [35][36][37] Fotoh and colleagues reported a patient with myeloma who had elevated triglyceride levels after bortezomib therapy. 38 In one case of bortezomib-associated pancreatitis, the patient had an elevated triglyceride level, but it was not extremely high.…”

Section: Proteosome Inhibitorsmentioning

confidence: 99%

Pancreatitis associated with newer classes of antineoplastic therapies

Clamon¹,

Patel²,

Mott³

2017

J Community Support Oncol

View full text Add to dashboard Cite

Newer anticancer therapies including tyrosine kinase inhibitors, immune modulators, immunotherapies, and chemotherapies have been reported to cause acute pancreatitis. This review gathers data from multiple case reports and small case series that associate these agents with pancreatitis. The mechanism of the pancreatitis may be direct toxicity, elevated triglycerides, immune mediated, or injury with direct injection into the liver, pancreas, or its blood supply. As abdominal pain, nausea, vomiting are associated with cancer chemotherapy itself, the diagnosis of acute pancreatitis might be missed.

show abstract

An unusual complication of bortezomib therapy: Acute pancreatitis

Cited by 9 publications

References 1 publication

Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient

Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient

Antineoplastic agents associated with the development of drug-induced pancreatitis

Pancreatitis associated with newer classes of antineoplastic therapies

Contact Info

Product

Resources

About